Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865506 | 0.81 | — | — | |
| SCHEMBL26550200 | 0.78 | — | — | |
| SCHEMBL7951142 | 0.74 | LRRK2 (0.33) | MEN1KMT2ARAB9AGFERLRRK2 | |
| SCHEMBL3706200 | 0.73 | CYP11B1 (0.35) | LRRK2CYP1A2CYP3A4 | |
| SCHEMBL30874428 | 0.72 | HSD17B10 (0.33) | LRRK2HSD17B10 | |
| SCHEMBL16847882 | 0.72 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL30032822 | 0.71 | — | — | |
| SCHEMBL22313600 | 0.71 | CYP2D6 (0.39) | MEN1KMT2ARAB9AGFERLRRK2 | |
| SCHEMBL30033684 | 0.71 | ALK (0.32) | LRRK2 | |
| SCHEMBL11916077 | 0.69 | CYP3A4 (0.38) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098210-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-31 | — | — | US | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020160175-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160174-A1 | USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098210-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | RECQL, XPO7, XPOT | MEN1 180/4885KMT2A 933/4885RAB9A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.